ATE516811T1 - Peptide vom g-typ zur linderung von atherosklerose - Google Patents

Peptide vom g-typ zur linderung von atherosklerose

Info

Publication number
ATE516811T1
ATE516811T1 AT03746574T AT03746574T ATE516811T1 AT E516811 T1 ATE516811 T1 AT E516811T1 AT 03746574 T AT03746574 T AT 03746574T AT 03746574 T AT03746574 T AT 03746574T AT E516811 T1 ATE516811 T1 AT E516811T1
Authority
AT
Austria
Prior art keywords
peptides
atherosclerosis
type peptides
relieving
relieving atherosclerosis
Prior art date
Application number
AT03746574T
Other languages
English (en)
Inventor
Alan Fogelman
Mohamad Navab
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE516811T1 publication Critical patent/ATE516811T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
AT03746574T 2002-04-05 2003-04-01 Peptide vom g-typ zur linderung von atherosklerose ATE516811T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/120,508 US6930085B2 (en) 2002-04-05 2002-04-05 G-type peptides to ameliorate atherosclerosis
PCT/US2003/009988 WO2003086326A2 (en) 2002-04-05 2003-04-01 G-type peptides to ameliorate atherosclerosis

Publications (1)

Publication Number Publication Date
ATE516811T1 true ATE516811T1 (de) 2011-08-15

Family

ID=28674643

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03746574T ATE516811T1 (de) 2002-04-05 2003-04-01 Peptide vom g-typ zur linderung von atherosklerose

Country Status (8)

Country Link
US (2) US6930085B2 (de)
EP (1) EP1496930B1 (de)
JP (1) JP4361809B2 (de)
CN (1) CN1658893B (de)
AT (1) ATE516811T1 (de)
AU (1) AU2003262142C1 (de)
CA (1) CA2480217C (de)
WO (1) WO2003086326A2 (de)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
MXPA05005031A (es) * 2002-11-12 2005-11-17 Becton Dickinson Co Diagnostico de la sepsis o sirs usando perfiles de biomarcadores.
DK1599173T3 (en) * 2002-11-13 2017-06-06 Uab Res Found SYNTHETIC SINGLE DOMAIN POLYPEPTIDES SIMILARING APOLIPOPROTEIN E AND PROCEDURES FOR THEIR USE
GB0305793D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Vaccine
ITRM20040098A1 (it) * 2004-02-25 2004-05-25 Univ Roma Anticorpi oligoclonali anticlasterina per la diagnosi di neoplasie e la predizione del loro grado di malignita', metodo diagnostico e kit relativi.
DE602005023428D1 (de) * 2004-04-15 2010-10-21 Athera Biotechnologies Ab Verfahren zur Feststellung der Gefahren von ischemischen Herzgefässerkrankungen mit PhosphorylcholinKonjugaten
JP2005318829A (ja) * 2004-05-07 2005-11-17 Shigeru Kinoshita 抗菌性ペプチド、該抗菌性ペプチドをコードするポリヌクレオチド、並びに該抗菌性ペプチドを含有する抗菌剤、抗菌性医薬、点眼薬及び眼感染症疾患検査薬
JP4880591B2 (ja) 2004-06-04 2012-02-22 テバ ファーマシューティカル インダストリーズ リミティド イルベサルタンを含む医薬組成物
US20060173067A1 (en) * 2004-08-11 2006-08-03 The Regents Of The University Of California Small molecules for the treatment of atherosclerosis
EP2801366A3 (de) * 2004-09-02 2015-04-29 Cognosci, Inc. Verbesserte ApoE-Analoga und Verwendungsverfahren dafür
CA2580501A1 (en) * 2004-09-16 2006-03-30 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
WO2006037800A1 (en) * 2004-10-08 2006-04-13 Université de Liège COMPLEMENTARY PEPTIDES FOR ß-AMYLOID 29-42 PEPTIDE
AU2005295640B2 (en) 2004-10-15 2011-07-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multi-domain amphipathic helical peptides and methods of their use
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
JP5087925B2 (ja) * 2004-12-07 2012-12-05 東レ株式会社 新規癌抗原ペプチド及びその用途
EP1869463A4 (de) 2005-04-15 2010-05-05 Becton Dickinson Co Sepsisdiagnose
MX2007013430A (es) 2005-04-29 2008-03-19 Univ California Peptidos y peptidos mimeticos para tratar patologias caracterizadas por una respuesta inflamatoria.
EP1836906B1 (de) * 2006-03-24 2009-07-01 Unilever N.V. Gesundes Nahrungsmittel
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
US20080199398A1 (en) * 2006-06-16 2008-08-21 Brewer H Bryan Novel Peptides That Promote Lipid Efflux
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
AU2007284801A1 (en) * 2006-08-08 2008-02-21 The Regents Of The University Of Californina Salicylanilides enhance oral delivery of therapeutic peptides
WO2008039843A2 (en) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
WO2008094905A2 (en) * 2007-01-29 2008-08-07 Lipid Sciences, Inc. Encapsulated hdl mimetic peptides
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
AU2008296478B9 (en) 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
CA2697504A1 (en) * 2007-08-29 2009-03-12 The Regents Of The University Of California Salicylanilide modified peptides for use as oral therapeutics
US8575107B2 (en) * 2008-01-22 2013-11-05 Compugen Ltd. Clusterin derived peptide
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
US8936787B2 (en) * 2008-04-15 2015-01-20 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Peptides promoting lipid efflux
ITTO20080894A1 (it) * 2008-12-02 2010-06-03 Bioindustry Park Del Canavese S P A Uso dell'aptoglobina, peptidi leganti l'aptoglobina, polimeri contenenti gli stessi e loro uso
WO2010103708A1 (ja) * 2009-03-13 2010-09-16 不二製油株式会社 抗アテローム性動脈硬化作用のあるジペプチド
US9241976B2 (en) 2011-08-29 2016-01-26 The Regents Of The University Of California Use of HDL-related molecules to treat and prevent proinflammatory conditions
JP6652781B2 (ja) * 2011-09-30 2020-02-26 ソマロジック・インコーポレーテッド 心血管系リスクイベントの予測およびその使用
US9539300B2 (en) 2012-03-31 2017-01-10 The Regents Of The University Of California Modulating disease through genetic engineering of plants
CN104812913B (zh) 2012-11-07 2019-03-15 私募蛋白质体公司 慢性阻塞性肺疾病(copd)生物标记及其用途
KR20170003611A (ko) 2014-05-02 2017-01-09 세레니스 쎄라퓨틱스 홀딩 에스에이 Ｈｄｌ 요법 마커
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
CA2961340C (en) 2014-09-26 2023-10-17 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof
CN105061579B (zh) * 2015-08-18 2018-08-28 北京大学人民医院 脂多糖结合蛋白在制备类风湿关节炎相关药物中的应用
MY184269A (en) * 2015-11-27 2021-03-30 Viramatix Sdn Bhd Broad-spectrum anti-influenza virus therapeutic peptides
BR112019001459A2 (pt) 2016-07-27 2019-05-07 Hartis-Pharma Sa combinação, composição farmacêutica, e, método de prevenção e/ou de tratamento de uma doença ou de um distúrbio.
US10905736B2 (en) 2016-09-28 2021-02-02 The Regents Of The University Of California Ezetimibe-associated ApoA-I mimetic peptides showing enhanced synergism
AU2017415108A1 (en) 2017-05-26 2019-12-19 Viramatix Sdn Bhd Peptides and uses therefor as antiviral agents

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3767040A (en) 1971-03-01 1973-10-23 Minnesota Mining & Mfg Pressure-sensitive polyurethane adhesives
US4155913A (en) 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
DE3933850A1 (de) * 1989-10-06 1991-04-18 Schering Ag Zytolyse-inhibitor (zli), eine diese blutplasmaprotein kodierende dna-sequenz, sowie ein plasmid, ein wirtsorganismus und ein verfahren zur gewinnung dieses proteins
AU662885B2 (en) 1990-06-07 1995-09-21 Scripps Research Institute, The APO AI polypeptides, antibodies, and immunoassays
JPH07507554A (ja) 1992-06-12 1995-08-24 エヌ・ブイ・イノゲネテイクス・エス・エイ 新規ペプチドおよびタンパク質，それらの調製方法，ならびにコレステロール受容体としてのそれらの使用
AU672028B2 (en) 1992-08-14 1996-09-19 Shino-Test Corporation Peptides containing respective amino acid sequences selected from among those of lipoprotein(a) and apolipoprotein(a), antibodies respectively recognizing these amino acid sequences, and method of assaying with these antibodies
EP0673387B1 (de) * 1992-12-11 1999-09-22 University Of Florida Materialien und methoden zur schädlingsbekämpfung
US5721138A (en) 1992-12-15 1998-02-24 Sandford University Apolipoprotein(A) promoter and regulatory sequence constructs and methods of use
ATE230600T1 (de) 1995-09-09 2003-01-15 Hoffmann La Roche Verwendung eines thienotriazoldiazepins zur erhöhung des apolopoproteins a-i niveaus
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
WO1997036927A1 (en) 1996-03-29 1997-10-09 Dario Boffelli Amphipathic molecules as cholesterol and other lipid uptake inhibitors
IN185761B (de) 1997-05-13 2001-04-28 Council Scient Ind Res
US6004925A (en) 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6518412B1 (en) 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en) 1997-09-29 2000-04-04 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en) 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6287590B1 (en) 1997-10-02 2001-09-11 Esperion Therapeutics, Inc. Peptide/lipid complex formation by co-lyophilization
AU3356899A (en) 1998-03-17 1999-10-11 Uab Research Foundation, The Synthetic peptides that enhance ldl uptake
AU3116800A (en) * 1998-12-11 2000-06-26 Research Foundation Of The State University Of New York, The Compositions and methods for altering cell migration
US20030165503A1 (en) * 2000-03-03 2003-09-04 Jean-Charles Fruchart Vaccine for the treatment of atherosclerosis
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
EP1186299A1 (de) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht Diagnose, Verbeugung und/oder Behandlung von Atherosklerose, Infectionen und Störungen des Immunsystems
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis

Also Published As

Publication number Publication date
EP1496930A2 (de) 2005-01-19
JP4361809B2 (ja) 2009-11-11
US20060258839A1 (en) 2006-11-16
HK1072896A1 (en) 2005-09-16
WO2003086326A2 (en) 2003-10-23
US20030191057A1 (en) 2003-10-09
AU2003262142B2 (en) 2009-03-26
EP1496930A4 (de) 2006-06-21
JP2005536456A (ja) 2005-12-02
AU2003262142C1 (en) 2009-08-13
CA2480217C (en) 2013-06-25
US7638494B2 (en) 2009-12-29
CN1658893B (zh) 2011-04-06
CN1658893A (zh) 2005-08-24
WO2003086326A3 (en) 2004-03-25
CA2480217A1 (en) 2003-10-23
US6930085B2 (en) 2005-08-16
AU2003262142A1 (en) 2003-10-27
EP1496930B1 (de) 2011-07-20

Similar Documents

Publication Publication Date Title
ATE516811T1 (de) Peptide vom g-typ zur linderung von atherosklerose
TNSN07396A1 (en) Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
WO2006034056A3 (en) G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
DE60141842D1 (de) Erosklerose
CY1125312T1 (el) Μικροκαψουλες παρατεταμενης αποδεσμευσης με βαση πολυ(λακτιδιο-συν-γλυκολιδιο) που περιεχουν ενα πολυπεπτιδιο και ενα σακχαρο
WO2009100348A3 (en) Peptides and peptide mimetics to treat pathologies associated with eye disease
CY1110177T1 (el) Ω-καρβοξυαρυλο υποκατεστημενες διφαινυλουριες ως αναστολεις της raf κινασης
DK1487493T3 (da) Konjugater af cytotoksiske midler og biologisk aktive peptider
CY1111225T1 (el) Νεα πεπτιδια ως αναστολεις πρωτεασης νs3-σερινης ιου ηπατiτιδας c
ATE424413T1 (de) Analoge des glucagon-ähnlichen peptids-1
NO20044898L (no) Nye etonogestrel estere
EA200700973A1 (ru) Слитый белок, содержащий домен bh3 белка «вh3-только»
ATE491349T1 (de) Neue nutrazeutika-zusammensetzungen
DE60233436D1 (de) In der mundhöhle dispergierbare feste pharmazeutische form
ATE323763T1 (de) Dna & protein bindende miniatur proteine
NO20011537L (no) Chemokin-reseptorpeptidvaksiner for behandling og forebygging av diabetes
EA200600404A1 (ru) Пероральные препаративные формы кладрибина
HRP20031057B1 (hr) Tableta koja sadrži cetirizin i pseudoefedrin
DE60318401D1 (de) Hydrierung von terephthalsäurerestehaltigen polyesteroligomeren
MA28724B1 (fr) NOUVELLE ASSOCIATION D'UN INHIBITEUR DU COURANT If SINUSAL ET D'UN IHIBITEUR CALCIQUE ET LES COMPOSITIONS PHARMACEUTIQUES QUI LA CONTIENNENT
WO2004111086A3 (fr) ANALOGUES PEPTIDIQUES COMPRENANT AU MOINS UN RESIDU AZA-ß3 AMINOACYLE, ET LEURS UTILISATIONS, NOTAMMENT EN THERAPIE
ATE506433T1 (de) Prozessierung von peptiden und proteinen
NO20024029D0 (no) Nytt protein og gen som koder for proteinet
FI20001207L (fi) Keinuhevonen tai vastaava keinulaute
DK1438341T3 (da) Antistoffer som stimulerer produktionen af IL-1Ra

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties